We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » New Direct Marking Requirements for UDIs - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - March 6, 2018

$287.00

Audio Recording/Transcript - March 6, 2018

$258.00

Audio Recording/Transcript - March 6, 2018

$244.00

Audio Recording/Transcript - March 6, 2018

$230.00

Audio Recording/Transcript - March 6, 2018

$215.00

New Direct Marking Requirements for UDIs - Webinar Recording/Transcript

$287.00
Webinar Recordings

Product Details

New Direct Marking Requirements for UDIs: How to Comply with the Final Guidance

The FDA’s final guidance on UDI (unique device identification) raises as many questions as it answers. With full compliance for Class I, II and unclassified devices looming, lawyers are hard at work parsing the FDA’s language.

The stakes for devicemakers are high. Getting compliance right spells profits, while getting it wrong spells penalties — and possible liability lawsuits too.

Jay Crowley was the architect of UDI while at the FDA. Now a consultant advising devicemakers, he remains the go-to expert on UDI compliance.

And Mr. Crowley is ready to tell all.

Spend 90 minutes with Mr. Crowley that readies you for full UDI compliance. In this presentation, you’ll discover: 

  • How the definition of “intended to be reprocessed” for purposes of UDI direct marking has changed from draft to final rule (it now identifies which devices are subject to the additional direct marking requirement)
  • Whether “single patient use” devices — ones which the patient reprocesses — fall under the direct mark requirement
  • What the final guidance says about how consigned or loaned devices will be treated for the purposes of the direct mark requirement
  • How long the FDA believes the direct mark UDI should last
  • How the existing-inventory exception affects those devices also subject to the direct mark requirement
  • FDA recordkeeping requirements for devices that must be directly marked
  • And much more!

Full compliance is looming. (Sept. 24, 2018, for Class II devices; Sept. 24, 2020, for Class I and unclassified devices.) Now is the time to sort out the likely impact of this key regulatory action.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing